GAS6 (D3A3G) Rabbit mAb #67202
- WB
- IHC
- IF
Supporting Data
REACTIVITY | H |
SENSITIVITY | Endogenous |
MW (kDa) | 78 |
Source/Isotype | Rabbit IgG |
Application Key:
- WB-Western Blotting
- IHC-Immunohistochemistry
- IF-Immunofluorescence
Species Cross-Reactivity Key:
- H-Human
Product Information
Product Usage Information
Application | Dilution |
---|---|
Western Blotting | 1:1000 |
Immunohistochemistry (Paraffin) | 1:50 |
Immunofluorescence (Immunocytochemistry) | 1:200 - 1:400 |
Storage
For a carrier free (BSA and azide free) version of this product see product #82314.
Protocol
Specificity / Sensitivity
GAS6 (D3A3G) Rabbit mAb recognizes endogenous levels of total GAS6 protein.
Species Reactivity:
Human
Source / Purification
Monoclonal antibody is produced by immunizing animals with recombinant protein specific to the amino terminus of human GAS6 protein.
Background
GAS6 (Growth Arrest Specific gene 6) is a vitamin K-dependent ligand of the TAM (Tyro3, Axl and MerTK) RTK family. It has an N-terminal Gla domain containing multiple Asp gamma-carboxylation sites, followed by four EGF repeats and two C-terminal LG domains. Vitamin K mediates multiple gamma-carboxylations of glutamic acid residues in the GAS6 Gla domain. These modifications are required for GAS6 to to activate its receptor (1,2). The two C-terminal LG (SHBG) domains form a V-shaped structure and provide a direct binding site for receptor interaction. Among the TAM family members, GAS6 has high affinity for Axl and low affinity for Tyro3 and MerTK. Ligand/receptor interaction activates multiple downstream signaling pathways such as PI3K/AKT, STAT/SOCS, PLC/FAK, and Grb2/RAS, and promotes cell survival, proliferation, migration and differentiation (3,4). GAS6 has been implicated in cancer development and immune-related disorders (inflammation and multiple sclerosis), and as such has been identified as a potential therapeutic target (3-6).
- Hafizi, S. and Dahlbäck, B. (2006) FEBS J 273, 5231-44.
- Davra, V. et al. (2016) Cancers (Basel) 8, 107.
- van der Meer, J.H. et al. (2014) Blood 123, 2460-9.
- Wu, G. et al. (2017) Cell Death Dis 8, e2700.
- Rothlin, C.V. et al. (2015) Annu Rev Immunol 33, 355-91.
- Bellan, M. et al. (2016) Int J Mol Sci 17, 1807.
Limited Uses
Except as otherwise expressly agreed in a writing signed by a legally authorized representative of CST, the following terms apply to Products provided by CST, its affiliates or its distributors. Any Customer's terms and conditions that are in addition to, or different from, those contained herein, unless separately accepted in writing by a legally authorized representative of CST, are rejected and are of no force or effect.
Products are labeled with For Research Use Only or a similar labeling statement and have not been approved, cleared, or licensed by the FDA or other regulatory foreign or domestic entity, for any purpose. Customer shall not use any Product for any diagnostic or therapeutic purpose, or otherwise in any manner that conflicts with its labeling statement. Products sold or licensed by CST are provided for Customer as the end-user and solely for research and development uses. Any use of Product for diagnostic, prophylactic or therapeutic purposes, or any purchase of Product for resale (alone or as a component) or other commercial purpose, requires a separate license from CST. Customer shall (a) not sell, license, loan, donate or otherwise transfer or make available any Product to any third party, whether alone or in combination with other materials, or use the Products to manufacture any commercial products, (b) not copy, modify, reverse engineer, decompile, disassemble or otherwise attempt to discover the underlying structure or technology of the Products, or use the Products for the purpose of developing any products or services that would compete with CST products or services, (c) not alter or remove from the Products any trademarks, trade names, logos, patent or copyright notices or markings, (d) use the Products solely in accordance with CST Product Terms of Sale and any applicable documentation, and (e) comply with any license, terms of service or similar agreement with respect to any third party products or services used by Customer in connection with the Products.